





Blood 142 (2023) 2156-2157

The 65th ASH Annual Meeting Abstracts

POSTER ABSTRACTS

721.ALLOGENEIC TRANSPLANTATION: CONDITIONING REGIMENS, ENGRAFTMENT AND ACUTE TOXICITIES

Sequential Conditioning Does Not Improve Outcomes of Allogeneic Stemcell Transplantation in CMML Patients

Radwan Massoud, BS, MD¹, Evgeny Klyuchnikov², Ameya Shrinivas Kunte, MD³, Christian Niederwieser, MD⁴, Dietlinde Janson³, Christine Wolschke⁴, Francis A. Ayuk, MD⁵, Nicolaus Kröger, MD⁶

¹Department of Stem Cell Transplantation, University Medical Center Hamburg Eppendorf, Hamburg, Germany

²Department of Stem Cell Transplantation, University Medical Center Hamburg Eppendorf, Hamburg, DEU

³Department of Stem Cell Transplantation, University Medical Center Hamburg Eppendorf, Hamburg, DEU

⁴Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

⁵Department of Stem Cell Transplantation with Research Department Cell and Gene Therapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

⁶Department of Stem Cell Transplantation with Research Department Cell and Gene Therapy University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Background:

Allogeneic stem cell transplantation (SCT) is potentially curative therapy for patients with CMML. Data on optimal allo-SCT conditioning in CMML Patients is scarce.

Methods:

This retrospective study from the Department of Stem Cell Transplantation at the University Medical Center Hamburg, Germany, compared allo-SCT outcomes in CMML patients across three conditioning regimes: Thiotepa-Busulfan (TB), Sequential FLAMSA-Busulfan Fludarabine (FLAMSA-FB), and Treosulfan-Fludarabine (Treo-Flu). TB consisted of Thiotapa (5mg/Kg; a total dose of 10mg/Kg) on day -6 and -5 and Busulfan (3.2mg/Kg; total dose 6.4mg/Kg or 9.6mg/Kg) on days -4 and -3 or -4 to -2. FLAMSA-FB regimen consists of fludarabine ($30 mg/m^2$; total dose $120 mg/m^2$), amsacrine ($100 mg/m^2$; total dose $400 mg/m^2$), and cytarabine ($1 g/m^2$; total dose $4 g/m^2$) therapy from days -11 to minus -8, followed by a three-day interval without therapy and Busulfan from day -4 to -2 with a total dose of 6.4mg/Kg and Fludarabine on day -4 and -3 ($30 mg/m^2$, total dose $60mg/m^2$). Treo-Flu regimen consisted of Treosulfan ($12 g/m^2$, total dose $36 mg/m^2$) on days-6 to -4 and fludarabine ($30 mg/m^2$; total dose $150 mg/m^2$) on days -6 to -2.

Results

Sixty-nine consecutive patients with CMML who underwent allo-SCT between the years 2006-2022. Twenty-two received TB, 27 received FLAMSA-FB, and 20 received Treo-Flu conditioning. Transplant sources included matched related donors (MRD, 8 patients), mismatched related donors (MMRD, 8 from TB), matched unrelated donors (MUD, 31), and mismatched unrelated donors (MMUD, 23) with significant group variations (p<0.001). Most Patients received ATLG for GVHD prophylaxis (TB 68%, FLAMSA-FB 93%, Treo-Flu 85%, p=0.08). Regarding CPSS-mol scores, the TB group exhibited a significantly higher proportion of high (46%) and intermediate-2 scores (32%) than FLAMSA-FB (11% high, 7% intermediate-2) and Treo-Flu (40% high, 20% intermediate-2) (p=0.001). One TB patient experienced primary graft failure, but engraftment times were comparable across groups. Although not statistically significant (p=0.07), the TB group also displayed significantly higher 3-year OS rates (84%) compared to FLAMSA-FB (37%) and Treo-Flu (40%). The TB group also displayed significant differences were observed in 3-year non-relapse mortality (NRM) across the TB (17%), FLAMSA-FB (30%), and Treo-Flu (26%) groups (p=0.7). Interestingly, no TB patients relapsed at 3 years, contrasting with the FLAMSA-FB (30%), and Treo-Flu groups (43%, p=0.02). Lastly, cumulative incidences of acute GVHD grade II-IV (TB 41%, FLAMSA-FB 35%, Treo-Flu 30%, p=0.75) and all-grade chronic GVHD (TB 50%, FLAMSA-FB 65%, Treo-Flu 40%, p=0.35) were similar across groups.

Conclusion

Our study suggests that sequential conditioning with FLAMSA-FB does not improve Transplant outcomes in patients undergoing allo-SCT for CMML.

Disclosures No relevant conflicts of interest to declare.



Figure 1

https://doi.org/10.1182/blood-2023-188745